Global ACE Inhibitors Market

Top 5 Insights From The ACE Inhibitors Market Report 2023

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

According to The Business Research Company’s ACE Inhibitors Global Market Report 2023, the ACE inhibitors market is expected to show promising growth in the forecast period.

The global ACE inhibitors market is charting a course for growth, with a projected increase from $6.57 billion in 2022 to $6.90 billion in 2023, representing a commendable Compound Annual Growth Rate (CAGR) of 5%. This upward momentum is poised to persist, reaching $8.45 billion in 2027 at a CAGR of 5.2%.

  • Steady Advancement: The consistent CAGR underscores the significant role of ACE inhibitors in addressing hypertension and related disorders.

Driving Forces: Tackling the Hypertension Epidemic
The anticipated growth of the ACE inhibitors market is primarily attributed to the increasing prevalence of hypertension disorders worldwide. Hypertension, or high blood pressure, poses a significant health risk and necessitates effective management. ACE inhibitors, a group of medications, play a crucial role in treating and controlling hypertension by relaxing blood vessels, thereby reducing blood pressure and enhancing blood flow.

  • Global Health Concern: According to the World Health Organization (WHO), approximately 1.28 billion adults aged 30 to 79 were affected by hypertension globally in March 2023. Two-thirds of these individuals reside in low- and middle-income nations, emphasizing the global impact of hypertension.
  • Alarming Statistics: Over the past 30 years, the number of adults aged 30-79 with hypertension has surged by 650 million. Shockingly, an estimated 46% of individuals with hypertension are unaware of their condition due to a lack of diagnosis.

Industry Titans: Leaders in the ACE Inhibitors Market
Major players are steering the ACE inhibitors market, contributing significantly to its growth and development. Recognizable names include Pfizer Inc., Novartis AG, Johnson & Johnson, and Merck KGaA.

  • Key Market Players: Other influential contributors encompass Sanofi S.A., Bayer AG, United Therapeutics Corporation, Teva Pharmaceutical Industry, Bristol-Myers Squibb, Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB (Schwarz Pharma Inc.), Solvay Pharmaceuticals B.V., Endo International, and Otto Brandes GmbH.

Innovation on the Horizon: Transforming Treatment
Product innovations emerge as a pivotal trend in the ACE inhibitors market, with major companies focusing on developing groundbreaking products to bolster their market position. For instance, in February 2023, Travere Therapeutics announced FDA approval of FILSPARI™ (sparsentan), a non-immunosuppressive therapy for patients with IgA nephropathy (IgAN).

  • Revolutionary Treatment: FILSPARI™ is a first-of-its-kind therapy designed for adults with primary IgAN at risk of rapid disease progression. It is the only non-immunosuppressive therapy approved, offering a once-daily oral solution for effective treatment.

Market Segmentation: Navigating Diversity
The global ACE inhibitors market boasts a diverse segmentation, providing insights into the multifaceted nature of the industry.

  1. By Type:
    • Sulfhydryl-containing Agents
    • Dicarboxylate-containing Agents
    • Phosphonate-containing Agents
  2. By Drug:
    • Ramipril
    • Enalapril
    • Benazepril
    • Fosinopril
    • Captopril
    • Moexipril
    • Other Drugs
  3. By Dosage Form:
    • Oral Tablets
    • Oral Solutions
  4. By Application:
    • Heart Failure
    • Chronic Kidney Disease
    • Hypertension
    • Diabetes
    • Heart Attack
    • Other Applications
  5. By End-Users:
    • Hospitals
    • Online Drug Stores
    • Other End-Users

Regional Dynamics: North America Leads, Asia-Pacific Accelerates
In 2022, North America asserted its dominance as the largest region in the ACE inhibitors market, attributed to advanced healthcare infrastructure and research initiatives. However, the forecast signals a shift, with Asia-Pacific emerging as the fastest-growing region.

  • North America’s Dominance: The region’s proactive approach positions it as a frontrunner in the global market.
  • Asia-Pacific’s Ascendance: With a rising prevalence of chronic diseases and increased healthcare investments, Asia-Pacific is poised for significant growth in the ACE inhibitors market.

View More On The ACE Inhibitors Market Report 2023 –

 Request A Sample Of The Global ACE Inhibitors Market Report 2023:

 The ACE Inhibitors Global Market Report 2023offers a comprehensive overview on the ACE inhibitors market size, growth rate, trends and drivers, opportunities, strategies, and competitor landscape. The countries covered in the ACE inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The Table Of Content For The ACE Inhibitors Market Include:
1. ACE Inhibitors Market Executive Summary
2. ACE Inhibitors Market Segments
3. ACE Inhibitors Market Size And ACE Inhibitors Market Growth Rate
4. Key ACE Inhibitors Market Trends
5. Major ACE Inhibitors Market Drivers
25. Key Mergers And Acquisitions In The ACE Inhibitors Market
26. Top ACE Inhibitors Companies
27. ACE Inhibitors Market Opportunities And Strategies
28. ACE Inhibitors Market, Conclusions And Recommendations
29. Appendix

View More Related Reports –
Synthetic Biology Global Market Report 2023
Digestive Enzymes Global Market Report 2023
Alpha Mannosidosis Global Market Report 2023

Contact us at:
The Business Research Company:
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
Global Market Model: